drugset / Trial / NCT01044836

Safety and Pharmacokinetic Characteristics of HD203 in Healthy Male Volunteers

NCT01044836

Phase 1 Completed 42 enrolled Hanwha Chemical
RandomizedCrossoverQuadruple-blindBasic science

Summary

The purpose of this study is compare the safety and pharmacokinetic characteristics of HD203 with those of etanercept after subcutaneous injection in healthy male volunteers.

Timeline

Start
2010-01
Primary completion
2010-07
Completion
2010-08

Drugs

EvaluationDrugModalityDoseRoute
Subject HD203 Unknown 25 mg Subcutaneous

Indications

No indication recorded.